Well Clinic
All-round medical service centre
查詢或預約Enquiry or Appointment
查詢或預約Enquiry or Appointment
查詢或預約Enquiry or Appointment
Hong Kong Well Clinic understands the importance of vaccination and is committed to providing safe and effective vaccine services. We offer a wide range of vaccines, including influenza vaccine, pneumococcal vaccine, herpes zoster vaccine, HPV 9-valent vaccine, etc.
The 25/26 “Vaccination Subsidy Scheme” has been launched since 25 September 2025, and all eligible persons can receive the free injection under government subsidy. Well Clinic is being recognized by the Government to provide the service. As such, we will provide the free Seasonal Influenza Vaccine to eligible Hong Kong citizens, as to protect the public against the Seasonal Influenza Infection.
The following eligible persons, upon successful registration with the Electronic Health Record Sharing System (eHealth)^, can receive FREE injection of government-subsidized seasonal influenza vaccination (or HK$100 for intranasal vaccine):
– Persons of age 50 or above
– Pregnant women
– Children aged between 6 months and less than 18 years old or 18 years old or above but attending any secondary school in Hong Kong
– Intellectually disabled
– Recipients of Disability Allowance
– Recipients of standard rate of “100% Disabled” or “Requiring Constant Attendance” Under CSSA
– Persons aged 18 to 49 with chronic illness*
Non-eligible persons would receive the vaccination by paying HK$220 per dose of injected vaccine / HK$330 per dose of intranasal vaccine.
^New subsidy eligibility criteria effective for the 2025–26 season.
*Chronic illnesses include:
According to the Centre for Health Protection, receiving seasonal influenza vaccination can prevent from infecting seasonal influenza and its complications. The winter influenza usually starts in early January, as it takes about two weeks to develop antibodies, members of the public are advised to receive vaccination early for protection against seasonal influenza. Influenza can lead to severe illness or even death to the persons with chronic medical problems or the elderly. Therefore, it is recommended that the public who are aged 6 months or more to receive the vaccination (except those who are pregnant, are immunocompromised or have other contraindications) for protection against seasonal influenza.
Citizens who are interested in receiving flu vaccines this quarter can visit our medical centre or contact +852 5292 0089 by phone or WhatsApp for appointment.
For more detail of the Vaccination Subsidy Scheme, please check the link https://www.chp.gov.hk/tc/features/107880.html.
1 dose:$330
(Indicated for children aged below 9 and never had flu vaccine)
Vaccine Information
The Quadrivalent Influenza Intranasal Vaccine is a live attenuated vaccine that is administered directly through the nose without injection. After vaccination, it can stimulate the body’s punctual membrane response and cellular immune response to fight against influenza.
Target Group
For people aged 2 to 49 years, but not for certain special groups, such as children taking medication containing aspirin, asthmatics, immunocompromised persons, pregnant women, etc.
1 dose:$220
(Indicated for children aged below 9 and never had flu vaccine)
Vaccine Information
Fluarix Tetra is an inactivated influenza vaccine (IIV) made from inactivated (killed) virus and is suitable for most people, including pregnant women and the elderly.
Target Group
Individuals aged 6 months and above.
1 dose:$1600
Vaccine Information
The Prevnar 20 is indicated for adults aged 18 years and above for the prevention of invasive disease and pneumonia caused by pneumococcal bacteria. In addition to the original 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F), seven new serotypes have been added (8. 10A, 11A, 12F), which are associated with invasive pneumococcal disease (IPD), high lethality, and antibiotic resistance, 10A, 11A, 12F, 15B, 22F, 33F), making it the FDA-approved conjugate pneumococcal vaccine with the most serotypes covered.
1 dose:$1500
2 doses:$2800
3 doses:$4100
Vaccine Information
The HPV 9-valent Vaccine covers 9 viruses including HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. These 9 viruses cause cancers and lesions such as cervical, vulvar, vaginal and anal cancers.
The diseases caused by HPV are not limited to women. Men and women who have sexual experience can be infected. In addition, if a woman is infected with HPV, she may infect her newborn during childbirth.
Target Group
Injections should be given at 0-2-6 months, i.e. 3 doses within 6 months, with 2 months and 4 months in between.
2 doses:$4980
Vaccine Information
Herpes zoster, is a painful condition caused by the varicella zoster virus. Herpes zoster can affect people of all ages and is especially common in the elderly. Sometimes even the slightest touch of the skin can cause severe pain, which can seriously affect the daily life of the patient.
Recommended by the Centers for Disease Control and Prevention (CDC) as the herpes zoster vaccine of choice, the second generation Shingrix shingles vaccine is more effective than the first generation Zostavax shingles vaccine in preventing herpes zoster and the neurological pain associated with it, as well as reducing the risk of other complications. If you have received the first generation Zostavax Shingles vaccine, it is recommended to receive the second generation Shingrix Shingles vaccine.
**Two doses of this vaccine are required to provide long term protection, 2-6 months apart**.
Target Group
For high-risk individuals aged 18 years or above and individuals aged 50 years or above.
1 dose:$384
2 doses:$768
3 doses:$1250
Vaccine Information
Hepatitis B is a liver disease caused by the Hepatitis B Virus (HBV). Carriers of the virus are at risk of developing life-threatening chronic liver diseases such as cirrhosis and liver cancer. Hepatitis B vaccine contains purified Hepatitis B surface antigen, which has been proven to be safe and effective in preventing Hepatitis B virus infection and its complications, and is recommended for high-risk individuals.
Hepatitis B antigen and antibody test (within the last 3 months) is required before vaccination to confirm whether you are a carrier or have existing antibodies and whether you are suitable to receive the vaccination.
If no valid report is produced, additional blood test fee will be charged.
Target Group
suitable for people aged 16 or above.
Vaccination method
Intramuscular injection, a total of 3 doses are required for full effect.
Vaccination schedule
The second dose should be given one month after the first dose, and the third dose should be given six months after the second dose
1 dose:$2700
What is RSV?
RSV stands for Human Respiratory Syncytical virus (Respiratory Syncytical Virus, RSV), which can cause severe lower respiratory tract infections in children and older adults. It usually causes mild cold-like symptoms such as coughing, sneezing, runny nose, nasal congestion, chills, low-grade fever and loss of appetite. RSV tends to attack more the lower respiratory tract (bronchioles) than common cold, and thus produces sputum that blocks the tiny airways, which can cause “acute bronchiolitis”
It is difficult for the human immune system to develop immunity to it, so the course of the disease after infection will be longer than that of a common cold, which can last up to 2 weeks
Is rapid test for RSV available?
Yes, and using a cotton swab to obtain nasopharyngeal secretions. It is similar to the rapid test for influenza and COVID-19.
After obtaining the specimen, the results can be known in about 5 minutes, which can help doctors confirm the diagnosis and also allow patients and their families to be reassured
What are the treatments for RSV?
Currently, no specific drugs exist to treat RSV infection, so “symptomatic treatment” is mainly used, including hydration and electrolyte replacement, respiratory therapy, bronchodilators, etc.
Is RSV vaccine available?
A new RSV vaccine with a protective efficacy of 82.6% for adults aged 60 and above has been registered in Hong Kong.
In older adults with an underlying medical condition, such as cardiovascular disease and endocrine-metabolic disease, the vaccine is 94.6% effective.
Resources:
https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Arexvy/pdf/AREXVY.PD